ELVN

46.5300.26%
MK

Mika Kakefuda Derynck

Independent Director

Dr. Mika Kakefuda Derynck, M.D., is Independent Director of Enliven Therapeutics, Inc. from August 2021. She served as Executive Vice President of Therapeutic Head Oncology at Vir Biotechnology, Inc. since September 2024 until September 2025. She has served as an Independent Director of Enliven Therapeutics, Inc. since the closing of the Merger on February 23, 2023 and was appointed in connection with the closing of the Merger. Prior to the Merger, Dr. Derynck served as a member of the board of directors of Former Enliven since August 2021. She serves as Chief Medical Officer of Amunix Pharmaceuticals, Inc. She is an accomplished drug developer with experience in cancer research, including a 15-year career at Genentech/Roche. She has deep expertise in oncology drug development, which spans multiple therapeutic modalities, tumor types and all phases of development. During her tenure at Genentech/Roche, she oversaw the approvals and/or global development for over a dozen drugs, including Perjeta®, Avastin®, Tecentriq®, Cotellic®, ipatasertib, taselisib, pictilisib and apitolisib. Most recently, she served as the Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises and China Oncology Development. Dr. Derynck was also a Senior Group Medical Director of Exploratory Clinical Development at Genentech, serving as the development lead for multiple early-stage programs. Before Genentech, Dr. Derynck was an Assistant Clinical Professor in the UCSF Department of Cellular and Molecular Pharmacology and Division of Hematology / Oncology. Dr. Derynck holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. Dr. Derynck completed an internal medicine residency at Johns Hopkins, followed by a fellowship in Hematology / Oncology at UCSF and a postdoctoral fellowship at UCSF.

Positions